Shattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases

Reuters03-05

<a href="https://laohu8.com/S/STTK">Shattuck Labs</a> Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases

Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3 (TNFRSF25) for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617549318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617549318","market":"nz","top_or_hot":-1,"title":"Shattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/STTK\">Shattuck Labs</a> Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3 (TNFRSF25) for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/STTK\">Shattuck Labs</a> Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3 (TNFRSF25) for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbQMZnc:1","article_id":"2617549318","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617549318","pubTimestamp":1772710652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3  for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STTK":"Shattuck Labs, Inc."},"translate_title":"Shattuck Labs发布DR3阻断抗体治疗炎症和免疫介导疾病的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STTK":0.9},"content_text":"Shattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases\n    \n\n        Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3 (TNFRSF25) for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617549318","isCrawlerRequest":true}